Natalia Gorelik1, Santhosh Mauvva Venkatesh Reddy2, Robert E Turcotte3, Krista Goulding3, Sungmi Jung4, Thierry Alcindor5, Thomas I Powell2. 1. Department of Diagnostic Radiology, McGill University Health Center, Montreal, Quebec, Canada. natalia.gorelik@mail.mcgill.ca. 2. Department of Diagnostic Radiology, McGill University Health Center, Montreal, Quebec, Canada. 3. Division of Orthopaedic Surgery, McGill University Health Center, Montreal, Quebec, Canada. 4. Department of Pathology, McGill University Health Center, Montreal, Quebec, Canada. 5. Gerald Bronfman Department of Oncology, Division of Medical Oncology, McGill University Health Center, Montreal, Quebec, Canada.
Abstract
OBJECTIVE: To define the role of whole-body MRI (WBMRI) for initial staging and routine follow-up of myxoid liposarcoma (MLS). MATERIALS AND METHODS: A retrospective review of all the patients with MLS who underwent WBMRI for initial staging and routine follow-up at our institution between October 1, 2006, and September 30, 2016 was performed. Patient demographics, clinical presentation, imaging findings, tumor histology, and occurrence and location of metastatic disease were recorded. Thirty-three patients who underwent a total of 150 WBMRI examinations were included in the study. RESULTS: Nine patients (27%) were diagnosed with metastases between 0 and 60 months (median 10; interquartile range, 7-13) from the diagnosis of the primary tumor. The initial site of metastatic disease was extrapulmonary in all patients. Only two patients developed pulmonary metastases, which were diagnosed by CT chest 9 and 29 months after the diagnosis of extrapulmonary metastases. The first metastasis was diagnosed by WBMRI in seven patients (78%), by thoracic CT in one patient, and by abdominal CT in one patient. Eight of nine patients (89%) were asymptomatic at the time of diagnosis of the metastases. In seven patients (78%), WBMRI demonstrated metastases included within the field of view of, but occult on a contemporaneous CT scan. CONCLUSION: Our 10-year institutional experience demonstrates that WBMRI facilitates early detection of extrapulmonary MLS metastases before the onset of clinical symptoms and pulmonary metastases. WBMRI also depicts extrapulmonary metastases that are occult on CT scans. The current surveillance strategies are insufficient for screening for extrapulmonary MLS metastases.
OBJECTIVE: To define the role of whole-body MRI (WBMRI) for initial staging and routine follow-up of myxoid liposarcoma (MLS). MATERIALS AND METHODS: A retrospective review of all the patients with MLS who underwent WBMRI for initial staging and routine follow-up at our institution between October 1, 2006, and September 30, 2016 was performed. Patient demographics, clinical presentation, imaging findings, tumor histology, and occurrence and location of metastatic disease were recorded. Thirty-three patients who underwent a total of 150 WBMRI examinations were included in the study. RESULTS: Nine patients (27%) were diagnosed with metastases between 0 and 60 months (median 10; interquartile range, 7-13) from the diagnosis of the primary tumor. The initial site of metastatic disease was extrapulmonary in all patients. Only two patients developed pulmonary metastases, which were diagnosed by CT chest 9 and 29 months after the diagnosis of extrapulmonary metastases. The first metastasis was diagnosed by WBMRI in seven patients (78%), by thoracic CT in one patient, and by abdominal CT in one patient. Eight of nine patients (89%) were asymptomatic at the time of diagnosis of the metastases. In seven patients (78%), WBMRI demonstrated metastases included within the field of view of, but occult on a contemporaneous CT scan. CONCLUSION: Our 10-year institutional experience demonstrates that WBMRI facilitates early detection of extrapulmonary MLS metastases before the onset of clinical symptoms and pulmonary metastases. WBMRI also depicts extrapulmonary metastases that are occult on CT scans. The current surveillance strategies are insufficient for screening for extrapulmonary MLS metastases.
Entities:
Keywords:
Follow-up; Metastases; Myxoid liposarcoma; Staging; Whole-body magnetic resonance imaging
Authors: Louis-Charles Moreau; Robert Turcotte; Peter Ferguson; Jay Wunder; Paul Clarkson; Bas Masri; Marc Isler; Norbert Dion; Joel Werier; Michelle Ghert; Benjamin Deheshi Journal: Ann Surg Oncol Date: 2011-11-04 Impact factor: 5.344
Authors: M Lemeur; J-C Mattei; P Souteyrand; C Chagnaud; G Curvale; A Rochwerger Journal: Orthop Traumatol Surg Res Date: 2015-01-09 Impact factor: 2.256
Authors: Suzan E ten Heuvel; Harald J Hoekstra; Robert J van Ginkel; Esther Bastiaannet; Albert J H Suurmeijer Journal: Ann Surg Oncol Date: 2006-10-22 Impact factor: 5.344
Authors: Kenneth Sheah; Hugue A Ouellette; Martin Torriani; G Petur Nielsen; Susan Kattapuram; Miriam A Bredella Journal: Skeletal Radiol Date: 2007-12-21 Impact factor: 2.199
Authors: D B Pearlstone; P W Pisters; R J Bold; B W Feig; K K Hunt; A W Yasko; S Patel; A Pollack; R S Benjamin; R E Pollock Journal: Cancer Date: 1999-01-01 Impact factor: 6.860
Authors: Marco Fiore; Federica Grosso; Salvatore Lo Vullo; Elisabetta Pennacchioli; Silvia Stacchiotti; Andrea Ferrari; Paola Collini; Laura Lozza; Luigi Mariani; Paolo G Casali; Alessandro Gronchi Journal: Cancer Date: 2007-06-15 Impact factor: 6.860
Authors: Koeun Lee; Ho Young Park; Kyung Won Kim; Amy Junghyun Lee; Min A Yoon; Eun Jin Chae; Jeong Hyun Lee; Hye Won Chung Journal: J Clin Orthop Trauma Date: 2019-05-29
Authors: Varun Chowdhry; Saveli Goldberg; Thomas F DeLaney; Gregory M Cote; Ivan Chebib; Jason Kim; Santiago A Lozano-Calderón; Karen De Amorim Bernstein Journal: Sarcoma Date: 2018-11-01